TW202322804A - 作為GABA Aγ1 PAM的新穎吡啶并二氮呯衍生物 - Google Patents
作為GABA Aγ1 PAM的新穎吡啶并二氮呯衍生物 Download PDFInfo
- Publication number
- TW202322804A TW202322804A TW111136044A TW111136044A TW202322804A TW 202322804 A TW202322804 A TW 202322804A TW 111136044 A TW111136044 A TW 111136044A TW 111136044 A TW111136044 A TW 111136044A TW 202322804 A TW202322804 A TW 202322804A
- Authority
- TW
- Taiwan
- Prior art keywords
- methyl
- chloro
- difluorophenyl
- trifluoromethyl
- tetradecyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21198735 | 2021-09-24 | ||
| EP21198735.9 | 2021-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202322804A true TW202322804A (zh) | 2023-06-16 |
Family
ID=77924305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111136044A TW202322804A (zh) | 2021-09-24 | 2022-09-23 | 作為GABA Aγ1 PAM的新穎吡啶并二氮呯衍生物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230109111A1 (enExample) |
| EP (1) | EP4405356A1 (enExample) |
| JP (1) | JP7899312B2 (enExample) |
| KR (1) | KR20240065086A (enExample) |
| CN (1) | CN117957227A (enExample) |
| AR (1) | AR127127A1 (enExample) |
| AU (1) | AU2022351080A1 (enExample) |
| CA (1) | CA3229125A1 (enExample) |
| IL (1) | IL310444A (enExample) |
| TW (1) | TW202322804A (enExample) |
| WO (1) | WO2023046877A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI878507B (zh) | 2020-03-31 | 2025-04-01 | 瑞士商赫孚孟拉羅股份公司 | 作為 GABA A γ1 PAM 的新穎苯并二氮呯衍生物 |
| JP2024537773A (ja) | 2021-09-29 | 2024-10-16 | エフ. ホフマン-ラ ロシュ アーゲー | GABA Aγ1 PAMとしての新規ベンゾジアゼピン誘導体 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1185601A (en) * | 1981-02-27 | 1985-04-16 | Walter Hunkeler | Imidazodiazepines |
| WO2003082832A2 (en) * | 2002-03-28 | 2003-10-09 | Wisys Technology Foundation, Inc. | Anxiolytic agents with reduced sedative and ataxic effects |
| JP2012087069A (ja) * | 2010-10-15 | 2012-05-10 | Osaka Prefecture Univ | 1,4−ベンゾジアゼピン誘導体の製造方法および該誘導体 |
-
2022
- 2022-09-22 AR ARP220102559A patent/AR127127A1/es not_active Application Discontinuation
- 2022-09-23 IL IL310444A patent/IL310444A/en unknown
- 2022-09-23 AU AU2022351080A patent/AU2022351080A1/en active Pending
- 2022-09-23 WO PCT/EP2022/076467 patent/WO2023046877A1/en not_active Ceased
- 2022-09-23 EP EP22793720.8A patent/EP4405356A1/en active Pending
- 2022-09-23 KR KR1020247008988A patent/KR20240065086A/ko active Pending
- 2022-09-23 CA CA3229125A patent/CA3229125A1/en active Pending
- 2022-09-23 US US17/934,769 patent/US20230109111A1/en not_active Abandoned
- 2022-09-23 CN CN202280062998.0A patent/CN117957227A/zh active Pending
- 2022-09-23 JP JP2024518302A patent/JP7899312B2/ja active Active
- 2022-09-23 TW TW111136044A patent/TW202322804A/zh unknown
-
2024
- 2024-02-14 US US18/441,558 patent/US20240270744A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023046877A1 (en) | 2023-03-30 |
| EP4405356A1 (en) | 2024-07-31 |
| US20240270744A1 (en) | 2024-08-15 |
| CA3229125A1 (en) | 2023-03-30 |
| IL310444A (en) | 2024-03-01 |
| KR20240065086A (ko) | 2024-05-14 |
| JP7899312B2 (ja) | 2026-08-03 |
| CN117957227A (zh) | 2024-04-30 |
| AR127127A1 (es) | 2023-12-20 |
| AU2022351080A1 (en) | 2024-02-15 |
| US20230109111A1 (en) | 2023-04-06 |
| JP2024535343A (ja) | 2024-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI642666B (zh) | 作為GABA-A α5正向異位調節劑之新穎異㗁唑醚衍生物 | |
| TWI878507B (zh) | 作為 GABA A γ1 PAM 的新穎苯并二氮呯衍生物 | |
| TW202322802A (zh) | 作為GABA A γ1 PAM的新穎苯并二氮呯衍生物 | |
| JP7754839B2 (ja) | Gaba aガンマ1 pamとしてのベンゾジアゼピン誘導体 | |
| TW202330477A (zh) | 作為GABA A γ1 PAM的新穎苯并二氮呯衍生物 | |
| US20240270744A1 (en) | New pyrido diazepine derivatives as gaba a gamma1 pam | |
| US20240287082A1 (en) | New benzodiazepine derivatives as gaba a gamma1 pam | |
| CN118019745A (zh) | 作为GABAA γ1受体的正向变构调节剂的环庚二烯并-噻吩并-二氮杂䓬衍生物 | |
| JP2024528173A (ja) | Gabaaガンマ1 pamとしての新規シクロペンタ-チエノ-ジアゼピン誘導体 | |
| HK40103189A (en) | Pyrido diazepine derivatives as gaba a gamma1 pam | |
| HK40104205A (en) | Cyclohepta-thieno-diazepine derivatives as positive allosteric modulators of the gaba a gamma1 receptor |